Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Receives $4.79 Average Target Price from Brokerages

Shares of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) have received an average rating of “Hold” from the eleven ratings firms that are presently covering the company, MarketBeat Ratings reports. Eight research analysts have rated the stock with a hold recommendation, two have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $4.79.

A number of brokerages have recently commented on MRNS. EF Hutton Acquisition Co. I raised Marinus Pharmaceuticals to a “strong-buy” rating in a research report on Monday, September 30th. TD Cowen reiterated a “hold” rating on shares of Marinus Pharmaceuticals in a research report on Friday, October 25th. Oppenheimer raised shares of Marinus Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $6.00 price target on the stock in a research report on Monday, September 23rd. Jefferies Financial Group restated a “hold” rating and set a $0.50 price target (down from $5.00) on shares of Marinus Pharmaceuticals in a research note on Friday, October 25th. Finally, Truist Financial lowered shares of Marinus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, October 24th.

Institutional Trading of Marinus Pharmaceuticals

Hedge funds have recently bought and sold shares of the company. Point72 DIFC Ltd bought a new stake in Marinus Pharmaceuticals during the second quarter valued at about $28,000. AQR Capital Management LLC grew its stake in shares of Marinus Pharmaceuticals by 70.3% during the 2nd quarter. AQR Capital Management LLC now owns 31,333 shares of the biopharmaceutical company’s stock valued at $37,000 after acquiring an additional 12,934 shares during the period. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Marinus Pharmaceuticals during the 2nd quarter valued at approximately $64,000. World Investment Advisors LLC purchased a new stake in Marinus Pharmaceuticals in the 3rd quarter worth approximately $104,000. Finally, Squarepoint Ops LLC bought a new stake in Marinus Pharmaceuticals during the 2nd quarter worth approximately $206,000. Hedge funds and other institutional investors own 98.80% of the company’s stock.

Marinus Pharmaceuticals Trading Up 0.9 %

Shares of NASDAQ:MRNS opened at $0.54 on Wednesday. The stock has a market cap of $29.63 million, a PE ratio of -0.22 and a beta of 1.03. The stock’s fifty day simple moving average is $0.35 and its two-hundred day simple moving average is $1.02. Marinus Pharmaceuticals has a 1-year low of $0.22 and a 1-year high of $10.50.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.